Pharmacokinetics and Safety of Single-Dose Sotrovimab in High-Risk Children and Adolescents With Mild-to-Moderate COVID-19
Sotrovimab was well tolerated by children/adolescents (6 to <18 years) with mild-to-moderate COVID-19 at high risk of progression to severe disease. Pharmacokinetic parameters in adolescents (12 to <18 years) were generally similar to those reported in adult studies of sotrovimab.
Authors
- Andrew Skingsley (ORCID: https://orcid.org/0000-0003-4826-4585)
- Jill Walker
- Klaudia Steplewski
- Ahmed Nader
- Leah A Gaffney
- Jennifer Moore (ORCID: https://orcid.org/0000-0003-1300-7298)
- Daren Austin (ORCID: https://orcid.org/0000-0002-9346-5071)
- Jerzy Daniluk
- Scott Segal (ORCID: https://orcid.org/0000-0002-7647-6422)
- Alicia Aylott
- Amanda Peppercorn (ORCID: https://orcid.org/0000-0002-9162-2539)
- Yessica Sachdeva
- Nadia Noormohamed (ORCID: https://orcid.org/0000-0002-5669-107X)
- Phillip J. Yates
- Marjan Hezareh
- Charlene Parado
Institutions
- Age UK (GB)
- Chandler–Gilbert Community College (US)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (Poland) (PL)
- GlaxoSmithKline (Canada) (CA)
- VIR Biotechnology (United States) (US)
- Golden Gate University (US)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1093/jpids/piaf027
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00